BioTime Inc. (NYSE:BTX) said today that it expanded its OpRegen Phase I/IIa trial into the U.S. with 2 new trial sites. The company’s study is evaluating its OpRegen cell therapy in patients with advanced dry form age-related macular degeneration. The 2 U.S.-based trial sites will include ophthalmologists Dr. David Boyer from the Retina-Vitreous Associates Medical Group […]
BioTime Inc. (NYSE:BTX) and its subsidiary Cell Cure Neurosciences said today that it is establishing an 800 square meter cell manufacturing facility at the Hadassah University Hospital in Jerusalem. The manufacturing center will be staffed initially by 30 employees, according to the companies, and will be prepared to produce OpRegen for BioTime’s ongoing clinical trial […]
BioTime yesterday announced a new offering of shares to support the development and commercialization of its regenerative medicine technologies. BioTime and its subsidiaries develop regenerative technologies around pluripotent stem cells and cell-based therapies. Oppenheimer & Co will act as sole book-running manager for the offering, according to a press release. The company has not yet stated […]
Regenerative medicine company BioTime said today its subsidiary Cell Cure Neurosciences won a $2.2 million (ILS ₪8.4 million) grant from the Israel Innovation Authority of the Ministry of Economy and Industry. The grant will support the continued development of its cell-based therapeutic OpRegen, designed to treat severe stages of the dry form of age-related macular degeneration, a leading […]
Regenerative medicine company BioTime said this week it raised $20 million in a closed round and it inked a development and licensing deal between its subsidiary Orthocyte and orthobiological-focused Heraeus Medical. BioTime and its subsidiaries develop regenerative technologies around pluripotent stem cells and cell-based therapies. Alameda, Calif.-based BioTime said today it closed a direct offering of […]
The launch of a pivotal clinical trial next year for a “hybrid” procedure to treat atrial fibrillation patients will be an “inflection point” for cardiac surgical device maker AtriCure Inc.’s (NSDQ:ATRC) U.S. business, the company’s CEO said.
The pivotal clinical trial, which could lead to regulatory approval of the hybrid procedure to treat atrial fibrillation and is called DEEP AF, will involve expanding studies from six research centers to 35, CEO David Drachman said.
Stem cell technology developer Cell Targeting Inc. sold its assets to BioTime Inc. (AMEX:BTX) in a deal worth about $2.3 million.
BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s common stock, which was trading around $7.75 at mid-day.